ACTRN12613000848707已完成未知
A randomised, placebo-controlled, double-blind, cross-over study of the effects of Magnesium supplementation on metabolic control in type 2 diabetic patients
Hospital General de Zona No 46. Instituto Mexicano del Seguro Social0 个研究点目标入组 100 人开始时间: 2013年8月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- All
入选标准
- •1. Type 2 diabetics with less than 15 years diagnosed.
- •2. Under treatment with diet, excercise or oral hypoglycemic agents.
- •3.- Adequate renal function
- •4.- Absence of any type of cancer
排除标准
- •1. Chronic kidney failure
- •2. Use of diuretics
- •3. Chronic diarrhea
- •4. Alcoholism
研究者
相似试验
终止
3 期
Opioids for breathlessness in people with mesothelioma or asbestosis or other causes of interstitial lung disease.ACTRN12611000711910Flinders University - Department of Palliative and Support Services39
进行中（未招募）
1 期
A randomised, placebo controlled, double-blind, cross-over trial of the Polypill on risk factor reduction - Polypill Prevention Trial 1 (PPT01)Hypercholesterolaemia and HypertensionMedDRA version: N/A Level: LLT Classification code 10020603 Term: HypercholesterolaemiaMedDRA version: N/A Level: LLT Classification code 10020772 Term: HypertensionEUCTR2010-019874-34-GBQueen Mary University of London
进行中（未招募）
不适用
A controlled study to look into reducing the number of times a patient suffering from an unexplained cough actually needs to cough by using the investigation medicine XEN-D0501.EUCTR2014-000306-36-GBXention Limited
进行中（未招募）
1 期
A clinical study to determine whether the medical product XEN-D0501 reduces the frequency of coughing in patients with chronic lung disease (chronic obstructive pulmonary disease).Chronic Obstructive Pulmonary Disease.MedDRA version: 17.0Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855EUCTR2013-004041-17-GBXention Limited
进行中（未招募）
不适用
A double-blind, randomised, placebo-controlled, crossover, allergen challenge study, evaluating the safety, tolerability and effects of intranasal administration of recombinant human Clara Cell 10 kDa (rhCC10) protein in subjects with allergic rhinitisEUCTR2006-005420-17-SETB4 Sweden AB